Table 3 Univariate analysis of overall and disease-specific survival for patients with OPSCC patients treated with resection

Age (> 65 y vs. < 65 y)

75.6/77.1

0.83

1.05 (0.66–1.68)

0.83

85.3/84.9

0.88

1.05 (0.56–1.99)

0.88

Smoking history (> 10 py vs. < 10 py)

70.9/88.5

0.002

2.53 (1.37–4.69)

0.003

80.8/95.8

0.003

4.19 (1.49–11.77)

0.006

Tumor stage (T3/T4 vs. T1/T2)

64.7/78.5

0.15

1.48 (0.87–2.55)

0.15

74.6/87.4

0.023

2.15 (1.09–4.21)

0.03

Nodal stage (N+ vs. N0)

73.5/82.0

0.31

1.3 (0.78–2.16)

0.31

83.2/90.2

0.14

1.77 (0.82–3.84)

0.15

HR-HPV DNA (Positive vs. negative)

85.9/66.8

< 0.001

0.39 (0.24–0.64)

< 0.001

91.6/78.9

< 0.001

0.30 (0.15–0.62)

0.001

p16^INK4a (High vs. low)

89.6/64.5

< 0.001

0.29 (0.15–0.44)

< 0.001

93.2/80.9

< 0.001

0.21 (0.1–0.46)

< 0.001

pRB (High vs. low)

67.6/85.5

< 0.001

2.68 (1.63–4.43)

< 0.001

78.8/92.2

< 0.001

3.56 (1.70–7.47)

0.001

Cyclin D1 (High vs. low)

67.6/82.0

0.009

1,79 (1.15–2.80)

0.01

81.9/87.7

0.068

1.76 (0.95–3.25)

0.07

p53 (High vs. low)

66.2/81.2

0.002

1.99 (1.27–3.10)

0.002

79.1/88.2

0.053

1.82 (0.98–3.36)

0.06

High p16^INK4a/HR-HPV DNA positive vs. others

85.9/66.8

< 0.001

0.39 (0.24–0.64)

< 0.001

91.6/78.9

< 0.001

0.30 (0.15–0.62)

0.001

High p16^INK4a/low pRB vs. others

87.7/67.0

< 0.001

0.32(0.18–0.54)

< 0.001

93.2/78.7

< 0.001

0.23 (0.10–0.52)

< 0.001

High p16^INK4a/low pRB/low cyclin D1/low p53 vs. others

88.3/69.9

< 0.001

0.33 (0.18–0.59)

< 0.001

94.1/80.0

< 0.001

0.21 (0.08–0.55)

0.001